Stockscreener 앱 받기
2.44
1.46%
0.035
시간 외 거래:
2.42
-0.02
-0.82%
전일 마감가:
$2.405
열려 있는:
$2.415
하루 거래량:
4.73M
Relative Volume:
0.53
시가총액:
$2.15B
수익:
$1.31M
순이익/손실:
$-597.65M
주가수익비율:
-2.5155
EPS:
-0.97
순현금흐름:
$-425.62M
1주 성능:
+2.95%
1개월 성능:
-9.96%
6개월 성능:
-27.38%
1년 성능:
-43.91%
1일 변동 폭
$2.38
$2.44
1주일 범위
$2.33
$2.46
52주 변동 폭
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
명칭
Immunitybio Inc
전화
(844) 696-5235
주소
3530 JOHN HOPKINS COURT, SAN DIEGO
IBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.44 | 2.25B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 개시 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | BTIG Research | Buy |
| 2023-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 개시 | Jefferies | Buy |
Immunitybio Inc 주식(IBRX)의 최신 뉴스
ImmunityBio Shareholder Settlement Gains Preliminary Approval, Boosting Company's Future Prospects - AInvest
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval - TipRanks
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Why Investors Shouldn't Be Surprised By ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Q2 2025 Revenue Up 5% YoY to $1,241mln; Raises FY23 Guidance, Innovation Target. - AInvest
ImmunityBio Q2 Earnings Show 60% Revenue Growth, $153.7 Million in Cash, and Strong Sales Momentum. - AInvest
ImmunityBio's ANKTIVA Receives Buy Rating Amid Expanding Oncology Potential and Market Growth - AInvest
ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth - AInvest
ImmunityBio 2025 Q2 Earnings Sustained Losses Amid Strong Revenue Surge - AInvest
ImmunityBio Reports Revenue Growth Amidst Continued Investments - TipRanks
ImmunityBio: Q2 Earnings Snapshot - Norwalk Hour
ImmunityBio's Q2 Net Loss Narrows, Revenue Rises - MarketScreener
ImmunityBio’s Revenue Jumps On Bladder Cancer Drug Success - Finimize
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
ImmunityBio: Boral Capital raises PT to $30, maintains Buy rating. - AInvest
ImmunityBio Q2 Financial Results: $92.6 Million LossNews and Statistics - IndexBox
Immunitybio Inc earnings beat, revenue topped estimates By Investing.com - Investing.com India
ImmunityBio, Inc. SEC 10-Q Report - TradingView
Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.10 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
Immunitybio Inc earnings beat, revenue topped estimates - Investing.com
ImmunityBio Q2 revenue up 60%, surpassing market estimates, on strong sales of ANKTIVA - MarketScreener
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code - Yahoo Finance
ImmunityBio (IBRX) Announces Preliminary Financial Results for the Quarter Ended June 30 - MSN
Watch for Trend Continuation in ImmunityBio Inc. Next WeekCapital Growth With Controlled Risk Picks Suggested - beatles.ru
ImmunityBio Inc. Moves Into Overbought Range Analysts CautiousReal-Time Market Sentiment Tracking Gains Momentum - metal.it
What are the technical indicators suggesting about ImmunityBio Inc.Consistent high-performance stocks - Jammu Links News
What is the dividend policy of ImmunityBio Inc. stockInvest smarter with daily stock recommendations - Jammu Links News
Is ImmunityBio Inc. a growth stock or a value stockFree Stock Market Real-Time Monitoring - Jammu Links News
How strong is ImmunityBio Inc. company’s balance sheetGet exclusive market insights for better trading - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
Should I hold or sell ImmunityBio Inc. stock in 2025Explosive trading growth - Jammu Links News
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations - MSN
What are analysts’ price targets for ImmunityBio Inc. in the next 12 monthsBuild a portfolio that stands the test of time - Jammu Links News
What are ImmunityBio Inc. company’s key revenue driversFree Stock Index Interpretation - Jammu Links News
What is ImmunityBio Inc. company’s growth strategyMassive portfolio appreciation - Jammu Links News
How many analysts rate ImmunityBio Inc. as a “Buy”Breakneck growth rates - Jammu Links News
What institutional investors are buying ImmunityBio Inc. stockInvest confidently with market-leading analysis - Jammu Links News
ImmunityBio’s Innovative Approach to Glioblastoma: A Promising Clinical Update - TipRanks
ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment - TipRanks
Immunitybio Inc (IBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):